Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR Inhibitors in Tuberous Sclerosis Complex

1 Dec 2012

Abstract excerpt

Tuberous sclerosis complex (TSC) is a genetic multiple organ system disorder that is characterized by the development of tumor-like lesions (hamartomas) and neurodevelopmental disorders. Mutations in the TSC1 and TSC2 tumor suppressor genes occur in the majority of patients with TSC, resulting in hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Polyomavirus and related diseases
Share to Tuberous Sclerosis Complex Research
Share to Vascular Tumors and Angiosarcomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23730262
DOI: 10.2174/157015912804143595

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR Inhibitors in Tuberous Sclerosis ComplexPMID 23730262Read ↗

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read ↗

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexSemantic proximity Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimusSemantic proximity Read ↗

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complexSemantic proximity Read ↗

Tuberous sclerosis complex.Semantic proximity Read ↗

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practiceSemantic proximity Read ↗

Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis ComplexSemantic proximity Read ↗

Tuberous sclerosis complex.Semantic proximity Read ↗

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complexSemantic proximity Read ↗

Genetics of tuberous sclerosis complex: implications for clinical practiceSemantic proximity Read ↗

Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.